Data investigation
The Drugs That Are Not Here Yet
Four investigational molecules have published human results. The most striking figure among them, 8% of body weight in four weeks, comes from the earliest and smallest study of the four.
Four molecules in development have published human results, and the most striking number among them, 8% of body weight in four weeks, comes from the earliest and smallest study of the four.[4] That is not a coincidence. Ranking these drugs by their headline figures ranks them by how short their trials were, and every one of them will reach peptide sellers before it reaches a pharmacy.
What has been published
| Drug | Stage | Weight change | Over |
|---|---|---|---|
| Aleniglipron (oral)[1] | Phase 2b, 230 people | −11.3% vs placebo at 120 mg | 36 weeks |
| Bofanglutide (biweekly)[2] | Phase 2b, 340 people | −9.75% to −16.69% vs −1.15% placebo | 30 weeks |
| CT-388[4] | Phase 1, people with overweight or obesity | −4.7% to −8.0% vs −0.5% placebo | 4 weeks |
| LY3537021 (GIP alone)[3] | Phase 1, 85 people | 3.14 kg vs 0.36 kg placebo at 25 mg | 57 days |
The finding worth caring about is not a weight number
LY3537021 is the least impressive drug in that table and the most interesting entry in it. It is a GIP receptor agonist on its own, with no GLP-1 component, which makes it an experiment on the question the whole field wants answered.
It produced dose-dependent weight loss that persisted 35 days after the last dose. And it did so with no delay in gastric emptying at any dose tested, and infrequent gastrointestinal side effects.
Weight came off without the stomach being slowed down.
That matters because delayed gastric emptying is where the nausea, vomiting and constipation come from, and those are why people stop (roughly one in ten in the trials covered elsewhere on this register). If GIP produces weight loss by a route that does not involve slowing the stomach, then the side effects and the benefit may be separable, which nobody has yet demonstrated in an approved drug.
Two cautions on the same result. The weight effect is modest at these doses, 3.14 kg against 0.36 kg on placebo. And the glucose effect did not hold: reductions in fasting glucose were transient and were no longer significantly different from placebo by day 29. On this evidence GIP alone looks like a weight drug rather than a diabetes drug, which is not what a GIP agonist was expected to be.
The biweekly one
Bofanglutide is designed to be injected once every two weeks. It posted the largest weight reduction in the table, up to 16.69% at 30 weeks against 1.15% on placebo, in 340 Chinese adults.
That is the disciplined version of something people already improvise. Stretching a weekly drug to fortnightly, to make it affordable, rests on a mathematical model and two patients (see stretching doses to save money). A molecule engineered for that interval and tested at it is a different proposition entirely. Amgen’s MariTide pushes the interval further, to monthly or less often, and is already in phase 3.
Two further limits on transferring that result. The trial used Chinese BMI thresholds, where overweight begins at 24 and obesity at 28 rather than the 25 and 30 used in the United States, so the population is lighter than a Western trial of the same labels. And the average participant was 33 years old.
What this means for what appears online
Every drug above is unapproved. None has a label, an approved manufacturer, or a legal route to a pharmacy. A published phase 2 result is the strongest free marketing a gray-market seller ever receives, and the pattern is established. In August 2026 our register counted eleven sellers already offering retatrutide, which is still unapproved everywhere; the details are in retatrutide’s phase 3 and the gray market.
- Phase 1 means safety and dose-finding, in tens of people, over weeks. It is not evidence a drug works.
- Phase 2b means a dose has been chosen and an effect estimated in a few hundred people. It is not evidence a drug is safe over years.
- A short trial flatters every drug in this class. Check the duration before the percentage.
- Certainty gradings exist. The BMJ synthesis of 262 trials rates the newest agents very low to low certainty (see what 262 trials say together).
One housekeeping note: the aleniglipron paper carries a publisher correction. It changes one figure value, the 120 mg arm’s change in Figure 3b from −12.1 to −12.7, and restores panels missing from Figure 4.[5] The −11.3% placebo-adjusted result in the table above comes from the abstract and is unchanged.
Frequently Asked Questions
References
- 1.Rosenstock J, Lingvay I, Ryan D, et al. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial Nature Medicine. 2026. PMID: 42249138.
- 2.Ji L, Gao L, Tian J, et al. Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial Signal Transduction and Targeted Therapy. 2026. PMID: 41760612.
- 3.Roell W, Alsina-Fernandez J, Qu H, et al. Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies Molecular Metabolism. 2026. PMID: 41391569.
- 4.Chakravarthy MV, Rodriguez R, Hergarden A, et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity Molecular Metabolism. 2026. PMID: 41319798.
- 5.Rosenstock J, Lingvay I, Ryan D, et al. Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial Nature Medicine. 2026. PMID: 42343118.
Compare the sellers
Related research
Is There a Tirzepatide Pill? What Sellers Ship
No tirzepatide pill is FDA-approved: Mounjaro and Zepbound are injections only. We list the sellers offering compounded tablets, drops and lozenges, what they charge, and the approved GLP-1 pills that do exist.
7 min read
The Dose That Stopped Helping
ACHIEVE-5 tested three doses of oral orforglipron on top of insulin in 546 adults with long-standing type 2 diabetes. Blood sugar improved at every dose, and the top dose was not better than the middle one.
6 min read
Wegovy Pill vs Injection: Is the Pill as Good as the Shot?
The Wegovy pill cut weight 13.6% in its trial and the shot 14.9% in its own, and an indirect comparison could not tell them apart. What differs: the daily fasting rule, the dose steps, side effects, the 7.2 mg pen and about $50 a month.
10 min read
An Oral Pill in a Diabetes Population
Over 72 weeks a daily tablet took 9.6% off the scale for people carrying obesity alongside type 2 diabetes. Why we will not set that figure beside the injectable trials.
7 min read
Comparing Trials That Never Met
We refused a cross-trial comparison in an earlier article. This article runs the methodologically proper version of it, and explains why it appears to contradict a head-to-head trial without actually doing so.
7 min read
The Top Dose Keeps Not Being Worth It
Orforglipron beat an SGLT2 inhibitor on blood sugar and lost badly on tolerability: one in five stopped taking it. And its top dose is the third in a row, across three trials, to buy almost nothing.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Direct Meds
Compounded semaglutide at $249/month
From $249/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo + membership
Get started →YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →